Given the link between Tfh cells, IL-21, and ANCA production, an IL-21 blockade could become a targeted strategy for treating AAV, potentially slowing disease progression and reducing relapse rates [55,56]. The gene discussed is IL21; the disease is anti-neutrophil cytoplasmic antibody-associated vasculitis.